PHARMACOLOGICAL MANAGEMENT OF PARKINSON’S DISEASE
*Sonawane A. R., Waghmare S. A. and Kamble H. V.
ABSTRACT
Parkinson’s disease (PD) is a disease that involves neurodegeneration and is characterised by the motor symptoms
which include muscle rigidity, tremor, and bradykinesia. Other non-motor symptoms include pain, depression,
anxiety, and psychosis. This disease affects up to ten million people worldwide. The pathophysiology behind PD
is due to the neurodegeneration of the nigrostriatal pathway. There are many conventional drugs used in the
treatment of PD. However, there are limitations associated with conventional drugs. For instance, levodopa is
associated with the on-off phenomenon, and it may induce wearing off as time progresses. PD is a
neurodegenerative illness and has a common onset between the ages of 55 and 65 years. There is progressive
development of both motor and non-motor symptoms, greatly affecting one’s overall quality of life. While there is
no cure, various treatments have been developed to help manage the symptoms of PD. Management of PD is a
growing field and targets new treatment methods, as well as improvements to old ones. Pharmacological, surgical,
and therapeutic treatments have allowed physicians to treat not only the main motor symptoms of PD, but target
patient-specific problems as they arise. This review discusses both the established and new possibilities for PD
treatment that can provide patient-specific care and mitigate side effects for common treatments.
Keywords: Neurodegeneration, bradykinesia,nigrostriatal pathway,levodopa,on-off phenomenon,quality of life.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
